Blackstone Inc’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-328,720
Closed -$7.4M 176
2024
Q1
$7.4M Hold
328,720
0.03% 91
2023
Q4
$7.04M Hold
328,720
0.03% 80
2023
Q3
$5.9M Hold
328,720
0.02% 95
2023
Q2
$6.69M Hold
328,720
0.03% 85
2023
Q1
$7.15M Hold
328,720
0.03% 85
2022
Q4
$10.2M Hold
328,720
0.04% 67
2022
Q3
$8.39M Hold
328,720
0.03% 73
2022
Q2
$6.67M Hold
328,720
0.02% 96
2022
Q1
$8.13M Hold
328,720
0.02% 113
2021
Q4
$11.4M Hold
328,720
0.03% 123
2021
Q3
$8.91M Buy
+328,720
New +$8.34M 0.02% 167

Other funds holding ANAB

Blackstone Inc's ANAB Position: Q2 2024 in Review

Blackstone Inc sold out of AnaptysBio (ANAB) in Q2 2024, closing a stake of 328,720 shares — an estimated $7.4M sold.

Blackstone Inc first reported a position in ANAB in Q3 2021 and held it in 11 quarters. The position peaked at $11.4M in Q4 2021. 135 funds tracked by Wall St. Rank hold ANAB as of Q2 2024.

  • Blackstone Inc reported no remaining AnaptysBio position as of Q2 2024 after selling out during the quarter.
  • Blackstone Inc sold 328,720 AnaptysBio shares in Q2 2024, an estimated $7.4M.
  • Blackstone Inc first reported a position in AnaptysBio in Q3 2021 and held it in 11 quarters.
  • Blackstone Inc's AnaptysBio position peaked at $11.4M in Q4 2021.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.